Data released today by AstraZeneca from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson’s rival treatment, analysts said.

The National Institute for Health and Care Excellence (NICE) said in draft final guidance that it estimates some 180,000 people could benefit from the new treatment.

At the recommendation of an independent data monitoring committee, J&J’s Janssen decided to stop the MACiTEPH trial in chronic thromboembolic pulmonary hypertension due to futility.

Biogen Inc. on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer’s disease drug being developed with Eisai Co. Ltd. and promising to draw lessons from the setbacks to its treatment Aduhelm.